Pharma Commercial Mock
← All views·CI feed·API docs
AASCO
Meeting Library
ESMO Congress 2026 · Barcelona, Spain
200 shown of 2,624 total abstracts
  1. Abstract 96822026-09-01 · 21:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Tecentriq in NSCLC (the IMpower-312 study)
    C. Robert, S. Tolaney, A. Spira, et al. · Royal Marsden Hospital
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  2. Abstract 91632026-09-04 · 19:15 CT · Hall B1
    Biomarker subgroup analysis of Tecentriq in NSCLC (the IMpower-742 study)
    M.C. Garassino, G. Curigliano, S. Tolaney · MD Anderson Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  3. Abstract 93922026-09-04 · 16:45 CT · E450
    Imfinzi plus chemotherapy in previously untreated NSCLC: updated analysis from PACIFIC-247
    P. Schmid, J. Cortes, T. Mok · MD Anderson Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  4. Abstract 91432026-09-02 · 15:45 CT · S406
    DESTINY-Breast-219: Enhertu (trastuzumab deruxtecan) adjuvant in NSCLC
    M. Krop, M.C. Garassino · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  5. Abstract 90022026-09-04 · 14:45 CT · S406
    Biomarker subgroup analysis of Keytruda in NSCLC (the KEYNOTE-388 study)
    A. Spira, S. Peters, M. Reck, et al. · Johns Hopkins Kimmel Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  6. Abstract 93822026-09-01 · 19:30 CT · S406
    Quality of life outcomes with Enhertu in patients with NSCLC
    C. Saura, S. Modi, R. Herbst · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  7. Abstract 93402026-09-02 · 21:00 CT · E450
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-546 study)
    E. Winer, G. Curigliano, S. Tolaney, et al. · Cleveland Clinic
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  8. Abstract 94582026-09-05 · 21:45 CT · E450
    PACIFIC-500: Imfinzi (durvalumab) maintenance in NSCLC
    S. Modi, P. Schmid · Royal Marsden Hospital
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  9. Abstract 98822026-09-03 · 16:30 CT · Hall B1
    Imfinzi plus chemotherapy in previously untreated NSCLC: updated analysis from PACIFIC-167
    G. Curigliano, R. Herbst, S. Peters · Peter MacCallum Cancer Centre
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  10. Abstract 98372026-09-03 · 18:00 CT · E450
    Enhertu plus chemotherapy in previously untreated NSCLC: updated analysis from DESTINY-Breast-120
    L. Paz-Ares, C. Saura · Johns Hopkins Kimmel Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  11. Abstract 97752026-09-03 · 15:30 CT · S406
    FLAURA-290: Tagrisso (osimertinib) 1L in NSCLC
    J. Cortes, G. Curigliano, H. Borghaei · Massachusetts General Hospital
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  12. Abstract 92102026-09-01 · 14:45 CT · S406
    Long-term follow-up of Keytruda maintenance for SCLC: KEYNOTE-631
    R. Herbst, J. Brahmer, G. Curigliano, et al. · Princess Margaret Cancer Centre
    Poster SessionLung Cancer—Small Cell📄🖼️
  13. Abstract 96742026-09-02 · 18:15 CT · Arie Crown Theater
    DESTINY-Breast-991: Enhertu (trastuzumab deruxtecan) 1L in NSCLC
    H. Rugo, C. Robert, R. Herbst · Massachusetts General Hospital
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  14. Abstract 96752026-09-02 · 14:30 CT · S406
    Real-world effectiveness of Keytruda vs standard of care in SCLC
    F. Andre, J. Brahmer, N. Rizvi · Cleveland Clinic
    Poster SessionLung Cancer—Small Cell📄🖼️
  15. Abstract 94592026-09-01 · 15:00 CT · Arie Crown Theater
    Long-term follow-up of Tecentriq adjuvant for NSCLC: IMpower-350
    J. Brahmer, E. Winer, S. Tolaney, et al. · Vall d'Hebron Institute of Oncology
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  16. Abstract 90402026-09-01 · 21:00 CT · Arie Crown Theater
    Real-world effectiveness of Imfinzi vs standard of care in SCLC
    L. Paz-Ares, J. Brahmer, C. Saura, et al. · Vall d'Hebron Institute of Oncology
    Poster SessionLung Cancer—Small Cell📄🖼️
  17. Abstract 96732026-09-04 · 21:15 CT · E450
    Long-term follow-up of Imfinzi 1L for NSCLC: PACIFIC-196
    J. Cortes, T. Mok, A. Spira, et al. · Peter MacCallum Cancer Centre
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  18. Abstract 93382026-09-03 · 18:45 CT · S406
    Real-world effectiveness of Imfinzi vs standard of care in NSCLC
    F. Andre, G. Curigliano, S. Peters, et al. · Princess Margaret Cancer Centre
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  19. Abstract 90182026-09-05 · 20:30 CT · S100A
    Biomarker subgroup analysis of Imfinzi in NSCLC (the PACIFIC-670 study)
    S. Tolaney, N. Rizvi, A. Spira, et al. · Johns Hopkins Kimmel Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  20. Abstract 93532026-09-03 · 15:45 CT · Hall B1
    Biomarker subgroup analysis of Keytruda in SCLC (the KEYNOTE-271 study)
    M. Reck, H. Rugo, T. Mok · Chinese University of Hong Kong
    Poster SessionLung Cancer—Small Cell📄🖼️
  21. Abstract 94752026-09-04 · 15:45 CT · E450
    Quality of life outcomes with Keytruda in patients with NSCLC
    M. Reck, R. Herbst · Royal Marsden Hospital
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  22. Abstract 94642026-09-05 · 20:00 CT · Hall B1
    Biomarker subgroup analysis of Imfinzi in SCLC (the PACIFIC-753 study)
    F. Andre, S. Antonia, C. Robert, et al. · Johns Hopkins Kimmel Cancer Center
    Poster SessionLung Cancer—Small Cell📄🖼️
  23. Abstract 97242026-09-05 · 15:00 CT · Hall B1
    Real-world effectiveness of Opdivo vs standard of care in NSCLC
    P. Schmid, E. Winer · University of Chicago
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  24. Abstract 98972026-09-01 · 13:45 CT · E450
    Real-world effectiveness of Enhertu vs standard of care in NSCLC
    G. Curigliano, S. Peters · Cleveland Clinic
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  25. Abstract 94892026-09-03 · 15:30 CT · S406
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-464 study)
    M.C. Garassino, C. Saura, M. Krop · Chinese University of Hong Kong
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  26. Abstract 98882026-09-05 · 15:00 CT · Arie Crown Theater
    FLAURA-881: Tagrisso (osimertinib) adjuvant in NSCLC
    C. Robert, P. Schmid · Mayo Clinic
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  27. Abstract 97892026-09-05 · 19:00 CT · S406
    FLAURA-871: Tagrisso (osimertinib) 2L in NSCLC
    L. Paz-Ares, M.C. Garassino · Royal Marsden Hospital
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  28. Abstract 97802026-09-05 · 18:45 CT · Arie Crown Theater
    PACIFIC-361: Imfinzi (durvalumab) adjuvant in NSCLC
    M.C. Garassino, R. Herbst, S. Tolaney, et al. · Johns Hopkins Kimmel Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  29. Abstract 98522026-09-03 · 20:30 CT · S100A
    Imfinzi plus chemotherapy in previously untreated SCLC: updated analysis from PACIFIC-270
    R. Herbst, L. Paz-Ares, N. Rizvi, et al. · Johns Hopkins Kimmel Cancer Center
    Poster SessionLung Cancer—Small Cell📄🖼️
  30. Abstract 91702026-09-03 · 15:00 CT · S406
    Real-world effectiveness of Tecentriq vs standard of care in NSCLC
    F. Andre, M. Reck, S. Antonia, et al. · Stanford Cancer Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  31. Abstract 99542026-09-04 · 13:00 CT · Hall B1
    Quality of life outcomes with Tagrisso in patients with NSCLC
    S. Peters, A. Spira, F. Andre, et al. · MD Anderson Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  32. Abstract 97212026-09-02 · 16:45 CT · S406
    Tecentriq plus chemotherapy in previously untreated NSCLC: updated analysis from IMpower-108
    J. Brahmer, M. Reck, G. Curigliano, et al. · National Cancer Center Japan
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  33. Abstract 96302026-09-04 · 13:45 CT · Arie Crown Theater
    FLAURA-499: Tagrisso (osimertinib) neoadjuvant in NSCLC
    J. Brahmer, M. Reck, H. Borghaei, et al. · National Cancer Center Japan
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  34. Abstract 91182026-09-02 · 16:00 CT · E450
    Biomarker subgroup analysis of Imfinzi in SCLC (the PACIFIC-686 study)
    P. Schmid, S. Peters · University of Chicago
    Poster SessionLung Cancer—Small Cell📄🖼️
  35. Abstract 99472026-09-04 · 18:30 CT · Arie Crown Theater
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-488
    P. Schmid, J. Cortes, G. Curigliano · Karolinska Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  36. Abstract 92562026-09-03 · 13:45 CT · S406
    Quality of life outcomes with Tecentriq in patients with NSCLC
    G. Curigliano, J. Cortes, M. Reck, et al. · Mayo Clinic
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  37. Abstract 91272026-09-01 · 15:15 CT · Hall B1
    Tecentriq plus chemotherapy in previously untreated NSCLC: updated analysis from IMpower-186
    H. Rugo, P. Schmid, A. Spira · Mayo Clinic
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  38. Abstract 94232026-09-05 · 18:45 CT · S406
    Biomarker subgroup analysis of Opdivo in NSCLC (the CheckMate-926 study)
    M. Krop, F. Andre · Memorial Sloan Kettering Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  39. Abstract 96432026-09-01 · 20:15 CT · Hall B1
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-2 study)
    S. Antonia, S. Peters, P. Schmid, et al. · Vall d'Hebron Institute of Oncology
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  40. Abstract 93032026-09-03 · 13:45 CT · E450
    Long-term follow-up of Imfinzi 1L for NSCLC: PACIFIC-941
    G. Curigliano, L. Paz-Ares, E. Winer · Mayo Clinic
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  41. Abstract 95642026-09-01 · 14:30 CT · S406
    Long-term follow-up of Imfinzi adjuvant for SCLC: PACIFIC-969
    G. Curigliano, M. Krop, S. Peters, et al. · MD Anderson Cancer Center
    Poster SessionLung Cancer—Small Cell📄🖼️
  42. Abstract 92592026-09-05 · 13:30 CT · E450
    Long-term follow-up of Tagrisso neoadjuvant for NSCLC: FLAURA-689
    M. Krop, C. Saura, P. Schmid, et al. · Vall d'Hebron Institute of Oncology
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  43. Abstract 99122026-09-01 · 13:30 CT · Arie Crown Theater
    PACIFIC-910: Imfinzi (durvalumab) 2L in SCLC
    N. Rizvi, H. Rugo · Vall d'Hebron Institute of Oncology
    Poster SessionLung Cancer—Small Cell📄🖼️
  44. Abstract 90262026-09-03 · 21:45 CT · S100A
    Biomarker subgroup analysis of Keytruda in SCLC (the KEYNOTE-309 study)
    S. Tolaney, J. Cortes, N. Rizvi, et al. · Karolinska Institute
    Poster SessionLung Cancer—Small Cell📄🖼️
  45. Abstract 91442026-09-01 · 15:00 CT · E450
    Biomarker subgroup analysis of Enhertu in NSCLC (the DESTINY-Breast-447 study)
    C. Robert, P. Schmid, N. Rizvi, et al. · Institut Gustave Roussy
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  46. Abstract 98872026-09-01 · 20:45 CT · Hall B1
    Opdivo plus chemotherapy in previously untreated NSCLC: updated analysis from CheckMate-805
    H. Borghaei, N. Rizvi, A. Spira, et al. · MD Anderson Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  47. Abstract 90422026-09-02 · 13:30 CT · S100A
    FLAURA-911: Tagrisso (osimertinib) adjuvant in NSCLC
    J. Cortes, T. Mok, G. Curigliano, et al. · Karolinska Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  48. Abstract 90832026-09-05 · 14:00 CT · S100A
    Biomarker subgroup analysis of Opdivo in NSCLC (the CheckMate-503 study)
    N. Rizvi, S. Peters, C. Robert · Dana-Farber Cancer Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  49. Abstract 92792026-09-05 · 14:00 CT · S406
    Biomarker subgroup analysis of Imfinzi in NSCLC (the PACIFIC-214 study)
    S. Tolaney, P. Schmid · Memorial Sloan Kettering Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  50. Abstract 99982026-09-02 · 19:15 CT · S406
    CheckMate-269: Opdivo (nivolumab) 3L+ in NSCLC
    E. Winer, F. Andre, C. Robert, et al. · MD Anderson Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  51. Abstract 93712026-09-03 · 14:15 CT · S406
    IMpower-835: Tecentriq (atezolizumab) adjuvant in NSCLC
    E. Winer, C. Robert, M. Reck · Karolinska Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  52. Abstract 93352026-09-03 · 15:15 CT · Arie Crown Theater
    IMpower-176: Tecentriq (atezolizumab) maintenance in NSCLC
    S. Peters, S. Tolaney · Mayo Clinic
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  53. Abstract 96512026-09-01 · 14:15 CT · S406
    Real-world effectiveness of Tagrisso vs standard of care in NSCLC
    S. Tolaney, S. Antonia, J. Brahmer · Mayo Clinic
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  54. Abstract 94872026-09-02 · 13:30 CT · S406
    Quality of life outcomes with Imfinzi in patients with NSCLC
    M.C. Garassino, J. Brahmer, P. Schmid, et al. · Chinese University of Hong Kong
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  55. Abstract 99012026-09-05 · 20:30 CT · Hall B1
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-172
    G. Curigliano, H. Rugo, M. Krop, et al. · Stanford Cancer Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  56. Abstract 93362026-09-01 · 14:00 CT · Arie Crown Theater
    FLAURA-892: Tagrisso (osimertinib) 2L in NSCLC
    G. Curigliano, A. Spira, S. Modi, et al. · Johns Hopkins Kimmel Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  57. Abstract 96492026-09-02 · 15:30 CT · Hall B1
    Tecentriq plus chemotherapy in previously untreated NSCLC: updated analysis from IMpower-1
    H. Rugo, P. Schmid, S. Peters · Massachusetts General Hospital
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  58. Abstract 94032026-09-03 · 18:15 CT · Arie Crown Theater
    Keytruda plus chemotherapy in previously untreated NSCLC: updated analysis from KEYNOTE-566
    S. Modi, J. Cortes, T. Mok, et al. · Vall d'Hebron Institute of Oncology
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  59. Abstract 92112026-09-01 · 21:30 CT · E450
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-578 study)
    H. Borghaei, E. Winer, M. Krop, et al. · Peter MacCallum Cancer Centre
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  60. Abstract 97462026-09-05 · 14:15 CT · Hall B1
    Long-term follow-up of Keytruda adjuvant for NSCLC: KEYNOTE-684
    E. Winer, P. Schmid, G. Curigliano, et al. · Cleveland Clinic
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  61. Abstract 92722026-09-04 · 14:45 CT · S100A
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-683
    S. Antonia, M.C. Garassino, M. Krop, et al. · Princess Margaret Cancer Centre
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  62. Abstract 97302026-09-04 · 19:30 CT · Arie Crown Theater
    Enhertu plus chemotherapy in previously untreated NSCLC: updated analysis from DESTINY-Breast-383
    G. Curigliano, C. Saura, M. Krop, et al. · Memorial Sloan Kettering Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  63. Abstract 94972026-09-05 · 18:45 CT · Hall B1
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-12
    F. Andre, N. Rizvi · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  64. Abstract 95392026-09-02 · 15:00 CT · Arie Crown Theater
    Opdivo plus chemotherapy in previously untreated NSCLC: updated analysis from CheckMate-14
    H. Rugo, S. Antonia · Massachusetts General Hospital
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  65. Abstract 97822026-09-04 · 18:30 CT · Arie Crown Theater
    Long-term follow-up of Imfinzi neoadjuvant for NSCLC: PACIFIC-542
    A. Spira, E. Winer, J. Brahmer · Cleveland Clinic
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  66. Abstract 95052026-09-02 · 14:45 CT · S406
    Long-term follow-up of Tagrisso 1L for NSCLC: FLAURA-276
    S. Tolaney, S. Modi, L. Paz-Ares, et al. · Stanford Cancer Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  67. Abstract 92882026-09-03 · 15:45 CT · S100A
    Tecentriq plus chemotherapy in previously untreated NSCLC: updated analysis from IMpower-852
    L. Paz-Ares, C. Robert, F. Andre, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  68. Abstract 97532026-09-01 · 14:45 CT · S100A
    Biomarker subgroup analysis of Enhertu in NSCLC (the DESTINY-Breast-401 study)
    S. Antonia, C. Saura · Princess Margaret Cancer Centre
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  69. Abstract 97432026-09-02 · 18:15 CT · S406
    Enhertu plus chemotherapy in previously untreated NSCLC: updated analysis from DESTINY-Breast-490
    S. Peters, H. Rugo, J. Brahmer · Princess Margaret Cancer Centre
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  70. Abstract 97992026-09-03 · 19:30 CT · Hall B1
    DESTINY-Breast-254: Enhertu (trastuzumab deruxtecan) adjuvant in NSCLC
    J. Brahmer, H. Borghaei, M.C. Garassino, et al. · Vall d'Hebron Institute of Oncology
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  71. Abstract 96782026-09-01 · 18:45 CT · S406
    Tecentriq plus chemotherapy in previously untreated NSCLC: updated analysis from IMpower-898
    F. Andre, H. Borghaei, N. Rizvi, et al. · Dana-Farber Cancer Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  72. Abstract 94242026-09-04 · 16:15 CT · Arie Crown Theater
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-402 study)
    G. Curigliano, H. Rugo · Dana-Farber Cancer Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  73. Abstract 97672026-09-03 · 21:15 CT · S406
    Real-world effectiveness of Keytruda vs standard of care in NSCLC
    M.C. Garassino, E. Winer, J. Brahmer, et al. · Dana-Farber Cancer Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  74. Abstract 91812026-09-01 · 13:45 CT · Arie Crown Theater
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-732
    M. Krop, S. Peters, J. Brahmer, et al. · Stanford Cancer Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  75. Abstract 97942026-09-01 · 14:45 CT · Hall B1
    KEYNOTE-840: Keytruda (pembrolizumab) maintenance in NSCLC
    J. Brahmer, S. Modi, C. Saura, et al. · Vall d'Hebron Institute of Oncology
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  76. Abstract 92922026-09-01 · 18:00 CT · S406
    Keytruda plus chemotherapy in previously untreated NSCLC: updated analysis from KEYNOTE-670
    C. Saura, F. Andre, T. Mok, et al. · University of Chicago
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  77. Abstract 94032026-09-03 · 18:30 CT · Arie Crown Theater
    Tecentriq plus chemotherapy in previously untreated NSCLC: updated analysis from IMpower-770
    C. Robert, S. Antonia · Chinese University of Hong Kong
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  78. Abstract 96112026-09-05 · 14:00 CT · Arie Crown Theater
    Biomarker subgroup analysis of Keytruda in NSCLC (the KEYNOTE-528 study)
    N. Rizvi, G. Curigliano · Memorial Sloan Kettering Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  79. Abstract 92442026-09-03 · 18:00 CT · Hall B1
    Quality of life outcomes with Keytruda in patients with SCLC
    S. Peters, A. Spira · Cleveland Clinic
    Poster SessionLung Cancer—Small Cell📄🖼️
  80. Abstract 99252026-09-01 · 18:15 CT · Hall B1
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-319 study)
    T. Mok, L. Paz-Ares, J. Brahmer, et al. · Massachusetts General Hospital
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  81. Abstract 96412026-09-02 · 13:15 CT · S100A
    KEYNOTE-168: Keytruda (pembrolizumab) adjuvant in SCLC
    E. Winer, T. Mok, P. Schmid · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionLung Cancer—Small Cell📄🖼️
  82. Abstract 98092026-09-05 · 15:45 CT · Arie Crown Theater
    Keytruda plus chemotherapy in previously untreated NSCLC: updated analysis from KEYNOTE-289
    C. Saura, L. Paz-Ares, M. Reck, et al. · Peter MacCallum Cancer Centre
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  83. Abstract 98302026-09-04 · 18:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Imfinzi in NSCLC (the PACIFIC-445 study)
    R. Herbst, H. Borghaei · MD Anderson Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  84. Abstract 99442026-09-05 · 15:00 CT · Arie Crown Theater
    Long-term follow-up of Imfinzi maintenance for SCLC: PACIFIC-169
    A. Spira, S. Tolaney, L. Paz-Ares · Mayo Clinic
    Poster SessionLung Cancer—Small Cell📄🖼️
  85. Abstract 94742026-09-01 · 14:30 CT · E450
    Imfinzi plus chemotherapy in previously untreated SCLC: updated analysis from PACIFIC-282
    R. Herbst, E. Winer · Chinese University of Hong Kong
    Poster SessionLung Cancer—Small Cell📄🖼️
  86. Abstract 90652026-09-05 · 15:30 CT · E450
    Long-term follow-up of Enhertu 2L for NSCLC: DESTINY-Breast-961
    E. Winer, T. Mok, S. Modi · Cleveland Clinic
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  87. Abstract 99402026-09-02 · 18:45 CT · Arie Crown Theater
    Long-term follow-up of Tagrisso adjuvant for NSCLC: FLAURA-654
    E. Winer, R. Herbst, G. Curigliano, et al. · Chinese University of Hong Kong
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  88. Abstract 97452026-09-04 · 13:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Enhertu in NSCLC (the DESTINY-Breast-968 study)
    F. Andre, S. Tolaney · Vall d'Hebron Institute of Oncology
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  89. Abstract 91152026-09-05 · 16:45 CT · Arie Crown Theater
    Imfinzi plus chemotherapy in previously untreated NSCLC: updated analysis from PACIFIC-524
    C. Robert, H. Rugo · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  90. Abstract 93482026-09-04 · 21:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-991 study)
    M. Krop, S. Peters, J. Brahmer · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  91. Abstract 96122026-09-05 · 18:45 CT · E450
    CheckMate-970: Opdivo (nivolumab) 3L+ in NSCLC
    P. Schmid, M.C. Garassino, H. Borghaei, et al. · Stanford Cancer Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  92. Abstract 93882026-09-03 · 16:30 CT · S406
    Biomarker subgroup analysis of Enhertu in NSCLC (the DESTINY-Breast-632 study)
    T. Mok, F. Andre, J. Brahmer · Princess Margaret Cancer Centre
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  93. Abstract 91922026-09-01 · 20:15 CT · Arie Crown Theater
    Imfinzi plus chemotherapy in previously untreated SCLC: updated analysis from PACIFIC-262
    M. Reck, L. Paz-Ares, C. Saura, et al. · Memorial Sloan Kettering Cancer Center
    Poster SessionLung Cancer—Small Cell📄🖼️
  94. Abstract 92722026-09-01 · 16:15 CT · S100A
    Long-term follow-up of Tagrisso 1L for NSCLC: FLAURA-949
    S. Modi, S. Antonia · Institut Gustave Roussy
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  95. Abstract 92712026-09-02 · 21:15 CT · S100A
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-146 study)
    S. Peters, S. Modi, J. Brahmer, et al. · Vall d'Hebron Institute of Oncology
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  96. Abstract 97232026-09-03 · 15:45 CT · S100A
    CheckMate-29: Opdivo (nivolumab) adjuvant in NSCLC
    G. Curigliano, R. Herbst, S. Modi, et al. · University of Chicago
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  97. Abstract 98822026-09-02 · 21:00 CT · Hall B1
    Long-term follow-up of Opdivo maintenance for NSCLC: CheckMate-259
    E. Winer, S. Tolaney, N. Rizvi, et al. · Dana-Farber Cancer Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  98. Abstract 99702026-09-04 · 18:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-225 study)
    M. Krop, R. Herbst, S. Antonia, et al. · Princess Margaret Cancer Centre
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  99. Abstract 91822026-09-05 · 19:15 CT · S100A
    Biomarker subgroup analysis of Opdivo in NSCLC (the CheckMate-796 study)
    S. Peters, S. Modi, C. Saura · Vall d'Hebron Institute of Oncology
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  100. Abstract 90302026-09-02 · 19:30 CT · S406
    Opdivo plus chemotherapy in previously untreated NSCLC: updated analysis from CheckMate-228
    S. Modi, S. Antonia, S. Peters · Chinese University of Hong Kong
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  101. Abstract 95252026-09-02 · 20:15 CT · S100A
    Quality of life outcomes with Imfinzi in patients with SCLC
    M.C. Garassino, L. Paz-Ares, H. Rugo, et al. · Dana-Farber Cancer Institute
    Poster SessionLung Cancer—Small Cell📄🖼️
  102. Abstract 99452026-09-05 · 20:45 CT · Arie Crown Theater
    Enhertu plus chemotherapy in previously untreated NSCLC: updated analysis from DESTINY-Breast-850
    A. Spira, J. Cortes, M.C. Garassino, et al. · Mayo Clinic
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  103. Abstract 97742026-09-03 · 13:00 CT · S406
    Long-term follow-up of Enhertu 2L for NSCLC: DESTINY-Breast-400
    P. Schmid, S. Modi, S. Tolaney, et al. · Karolinska Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  104. Abstract 93812026-09-03 · 19:30 CT · E450
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-415
    S. Modi, S. Antonia, L. Paz-Ares, et al. · Cleveland Clinic
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  105. Abstract 92492026-09-02 · 20:15 CT · S406
    FLAURA-600: Tagrisso (osimertinib) maintenance in NSCLC
    S. Tolaney, H. Borghaei, P. Schmid, et al. · Stanford Cancer Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  106. Abstract 97082026-09-03 · 13:30 CT · E450
    Tecentriq plus chemotherapy in previously untreated NSCLC: updated analysis from IMpower-179
    R. Herbst, J. Brahmer · Peter MacCallum Cancer Centre
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  107. Abstract 96842026-09-01 · 14:15 CT · Hall B1
    PACIFIC-251: Imfinzi (durvalumab) neoadjuvant in SCLC
    S. Antonia, M. Reck, J. Cortes, et al. · Johns Hopkins Kimmel Cancer Center
    Poster SessionLung Cancer—Small Cell📄🖼️
  108. Abstract 92542026-09-05 · 19:15 CT · Hall B1
    Biomarker subgroup analysis of Imfinzi in NSCLC (the PACIFIC-110 study)
    S. Peters, G. Curigliano · Massachusetts General Hospital
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  109. Abstract 98372026-09-02 · 21:15 CT · Arie Crown Theater
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-872 study)
    S. Tolaney, A. Spira, J. Cortes · Memorial Sloan Kettering Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  110. Abstract 99682026-09-03 · 13:00 CT · E450
    Keytruda plus chemotherapy in previously untreated SCLC: updated analysis from KEYNOTE-115
    S. Antonia, S. Modi, S. Tolaney · Institut Gustave Roussy
    Poster SessionLung Cancer—Small Cell📄🖼️
  111. Abstract 99122026-09-05 · 16:15 CT · S100A
    KEYNOTE-757: Keytruda (pembrolizumab) adjuvant in SCLC
    A. Spira, N. Rizvi · University of Chicago
    Poster SessionLung Cancer—Small Cell📄🖼️
  112. Abstract 99192026-09-01 · 19:00 CT · S100A
    PACIFIC-209: Imfinzi (durvalumab) adjuvant in SCLC
    M.C. Garassino, J. Brahmer, A. Spira, et al. · University of Chicago
    Poster SessionLung Cancer—Small Cell📄🖼️
  113. Abstract 97402026-09-01 · 19:45 CT · Arie Crown Theater
    Keytruda plus chemotherapy in previously untreated NSCLC: updated analysis from KEYNOTE-494
    J. Cortes, P. Schmid, L. Paz-Ares, et al. · National Cancer Center Japan
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  114. Abstract 97242026-09-04 · 21:00 CT · E450
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-926 study)
    M.C. Garassino, T. Mok, N. Rizvi, et al. · MD Anderson Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  115. Abstract 93672026-09-04 · 19:45 CT · Arie Crown Theater
    PACIFIC-234: Imfinzi (durvalumab) 2L in SCLC
    M.C. Garassino, S. Tolaney, E. Winer, et al. · Peter MacCallum Cancer Centre
    Poster SessionLung Cancer—Small Cell📄🖼️
  116. Abstract 92632026-09-05 · 20:45 CT · S406
    Biomarker subgroup analysis of Imfinzi in SCLC (the PACIFIC-989 study)
    S. Peters, S. Tolaney, P. Schmid, et al. · Johns Hopkins Kimmel Cancer Center
    Poster SessionLung Cancer—Small Cell📄🖼️
  117. Abstract 95142026-09-01 · 19:00 CT · Arie Crown Theater
    Biomarker subgroup analysis of Tecentriq in NSCLC (the IMpower-877 study)
    H. Rugo, R. Herbst · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  118. Abstract 98302026-09-03 · 20:15 CT · S406
    Long-term follow-up of Imfinzi 1L for NSCLC: PACIFIC-229
    H. Borghaei, G. Curigliano · Peter MacCallum Cancer Centre
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  119. Abstract 95262026-09-04 · 18:45 CT · Hall B1
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-995 study)
    S. Peters, F. Andre, L. Paz-Ares, et al. · MD Anderson Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  120. Abstract 99312026-09-04 · 16:15 CT · E450
    FLAURA-579: Tagrisso (osimertinib) 3L+ in NSCLC
    M.C. Garassino, S. Modi, H. Rugo, et al. · Karolinska Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  121. Abstract 95462026-09-05 · 13:30 CT · Arie Crown Theater
    PACIFIC-115: Imfinzi (durvalumab) adjuvant in NSCLC
    C. Robert, G. Curigliano · Royal Marsden Hospital
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  122. Abstract 98962026-09-03 · 20:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Keytruda in SCLC (the KEYNOTE-871 study)
    M. Krop, C. Robert · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionLung Cancer—Small Cell📄🖼️
  123. Abstract 91192026-09-03 · 13:00 CT · E450
    Biomarker subgroup analysis of Tecentriq in NSCLC (the IMpower-27 study)
    S. Peters, M. Reck, M. Krop, et al. · Mayo Clinic
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  124. Abstract 97692026-09-02 · 13:15 CT · Arie Crown Theater
    FLAURA-634: Tagrisso (osimertinib) neoadjuvant in NSCLC
    C. Saura, J. Brahmer · Memorial Sloan Kettering Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  125. Abstract 98152026-09-01 · 20:15 CT · Hall B1
    Long-term follow-up of Imfinzi 2L for SCLC: PACIFIC-453
    S. Modi, S. Tolaney · Karolinska Institute
    Poster SessionLung Cancer—Small Cell📄🖼️
  126. Abstract 91782026-09-01 · 18:45 CT · S100A
    PACIFIC-491: Imfinzi (durvalumab) maintenance in SCLC
    J. Brahmer, G. Curigliano, N. Rizvi, et al. · Karolinska Institute
    Poster SessionLung Cancer—Small Cell📄🖼️
  127. Abstract 93782026-09-01 · 16:15 CT · Arie Crown Theater
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-823
    H. Borghaei, R. Herbst, S. Peters, et al. · Mayo Clinic
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  128. Abstract 99532026-09-03 · 21:00 CT · Arie Crown Theater
    Biomarker subgroup analysis of Keytruda in SCLC (the KEYNOTE-87 study)
    S. Antonia, M. Krop, S. Tolaney, et al. · National Cancer Center Japan
    Poster SessionLung Cancer—Small Cell📄🖼️
  129. Abstract 96912026-09-03 · 20:15 CT · Hall B1
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-637 study)
    M. Reck, C. Robert, S. Peters, et al. · Stanford Cancer Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  130. Abstract 91982026-09-03 · 18:45 CT · E450
    Tecentriq plus chemotherapy in previously untreated NSCLC: updated analysis from IMpower-202
    C. Saura, S. Tolaney, M. Reck · Massachusetts General Hospital
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  131. Abstract 91622026-09-04 · 13:00 CT · S406
    Opdivo plus chemotherapy in previously untreated NSCLC: updated analysis from CheckMate-736
    M. Reck, C. Saura, C. Robert, et al. · University of Chicago
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  132. Abstract 94252026-09-02 · 13:15 CT · E450
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-462 study)
    F. Andre, S. Antonia · Cleveland Clinic
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  133. Abstract 96342026-09-04 · 20:15 CT · Arie Crown Theater
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-982 study)
    J. Cortes, N. Rizvi, T. Mok · Memorial Sloan Kettering Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  134. Abstract 98212026-09-03 · 21:45 CT · Hall B1
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-630
    J. Brahmer, F. Andre · Mayo Clinic
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  135. Abstract 96732026-09-01 · 14:45 CT · E450
    Long-term follow-up of Tagrisso 1L for NSCLC: FLAURA-651
    S. Peters, P. Schmid · Institut Gustave Roussy
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  136. Abstract 91852026-09-02 · 13:15 CT · Hall B1
    CheckMate-317: Opdivo (nivolumab) 3L+ in NSCLC
    L. Paz-Ares, E. Winer, F. Andre, et al. · Peter MacCallum Cancer Centre
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  137. Abstract 91942026-09-03 · 14:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Keytruda in NSCLC (the KEYNOTE-47 study)
    T. Mok, E. Winer · University of Chicago
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  138. Abstract 96842026-09-02 · 14:15 CT · E450
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-198 study)
    G. Curigliano, L. Paz-Ares, N. Rizvi · Princess Margaret Cancer Centre
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  139. Abstract 99542026-09-05 · 21:45 CT · S406
    DESTINY-Breast-617: Enhertu (trastuzumab deruxtecan) 3L+ in NSCLC
    N. Rizvi, S. Modi · Princess Margaret Cancer Centre
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  140. Abstract 97952026-09-05 · 15:45 CT · E450
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-861 study)
    J. Cortes, C. Robert, S. Antonia, et al. · Mayo Clinic
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  141. Abstract 90382026-09-03 · 15:30 CT · S100A
    Biomarker subgroup analysis of Keytruda in SCLC (the KEYNOTE-963 study)
    M. Krop, S. Antonia, M.C. Garassino · Memorial Sloan Kettering Cancer Center
    Poster SessionLung Cancer—Small Cell📄🖼️
  142. Abstract 90452026-09-04 · 16:30 CT · E450
    Biomarker subgroup analysis of Keytruda in SCLC (the KEYNOTE-987 study)
    N. Rizvi, P. Schmid, H. Borghaei · Stanford Cancer Institute
    Poster SessionLung Cancer—Small Cell📄🖼️
  143. Abstract 93692026-09-02 · 21:30 CT · Arie Crown Theater
    Quality of life outcomes with Opdivo in patients with NSCLC
    M. Krop, F. Andre, S. Antonia, et al. · Royal Marsden Hospital
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  144. Abstract 91182026-09-03 · 14:45 CT · Hall B1
    Long-term follow-up of Imfinzi 1L for NSCLC: PACIFIC-684
    R. Herbst, M. Krop, T. Mok, et al. · Vall d'Hebron Institute of Oncology
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  145. Abstract 95102026-09-02 · 20:45 CT · Hall B1
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-198
    S. Antonia, H. Borghaei · Mayo Clinic
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  146. Abstract 98162026-09-01 · 14:45 CT · S406
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-809 study)
    M. Krop, H. Rugo, J. Brahmer, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  147. Abstract 98432026-09-01 · 18:15 CT · Arie Crown Theater
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-492
    N. Rizvi, C. Robert, S. Tolaney, et al. · Memorial Sloan Kettering Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  148. Abstract 94042026-09-01 · 18:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Keytruda in SCLC (the KEYNOTE-780 study)
    J. Brahmer, F. Andre, H. Rugo · National Cancer Center Japan
    Poster SessionLung Cancer—Small Cell📄🖼️
  149. Abstract 98342026-09-01 · 19:30 CT · Hall B1
    Long-term follow-up of Enhertu 3L+ for NSCLC: DESTINY-Breast-918
    P. Schmid, F. Andre, M. Reck, et al. · Stanford Cancer Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  150. Abstract 96052026-09-02 · 13:00 CT · S100A
    FLAURA-686: Tagrisso (osimertinib) 2L in NSCLC
    N. Rizvi, T. Mok · National Cancer Center Japan
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  151. Abstract 91132026-09-05 · 21:15 CT · E450
    Imfinzi plus chemotherapy in previously untreated NSCLC: updated analysis from PACIFIC-404
    G. Curigliano, P. Schmid, M.C. Garassino · Karolinska Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  152. Abstract 93132026-09-03 · 16:30 CT · S406
    Biomarker subgroup analysis of Opdivo in NSCLC (the CheckMate-293 study)
    G. Curigliano, N. Rizvi, C. Saura, et al. · Dana-Farber Cancer Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  153. Abstract 99392026-09-04 · 19:45 CT · S406
    Biomarker subgroup analysis of Keytruda in NSCLC (the KEYNOTE-812 study)
    S. Modi, H. Rugo, F. Andre, et al. · Princess Margaret Cancer Centre
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  154. Abstract 92332026-09-04 · 20:15 CT · Arie Crown Theater
    Imfinzi plus chemotherapy in previously untreated NSCLC: updated analysis from PACIFIC-568
    R. Herbst, M.C. Garassino, S. Peters, et al. · Princess Margaret Cancer Centre
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  155. Abstract 97132026-09-03 · 18:00 CT · S100A
    Long-term follow-up of Imfinzi neoadjuvant for SCLC: PACIFIC-959
    L. Paz-Ares, A. Spira, S. Antonia, et al. · Royal Marsden Hospital
    Poster SessionLung Cancer—Small Cell📄🖼️
  156. Abstract 91762026-09-05 · 13:00 CT · S406
    Long-term follow-up of Tagrisso 1L for NSCLC: FLAURA-26
    C. Saura, N. Rizvi, S. Antonia, et al. · Chinese University of Hong Kong
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  157. Abstract 93622026-09-04 · 14:15 CT · Hall B1
    PACIFIC-972: Imfinzi (durvalumab) neoadjuvant in SCLC
    C. Robert, J. Cortes, H. Rugo, et al. · MD Anderson Cancer Center
    Poster SessionLung Cancer—Small Cell📄🖼️
  158. Abstract 99542026-09-04 · 20:15 CT · Hall B1
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-386 study)
    N. Rizvi, M. Reck · Massachusetts General Hospital
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  159. Abstract 95632026-09-01 · 13:45 CT · Arie Crown Theater
    FLAURA-7: Tagrisso (osimertinib) 3L+ in NSCLC
    R. Herbst, F. Andre, M.C. Garassino, et al. · Mayo Clinic
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  160. Abstract 94872026-09-04 · 15:30 CT · S406
    FLAURA-314: Tagrisso (osimertinib) 3L+ in NSCLC
    P. Schmid, M. Krop, J. Brahmer · Stanford Cancer Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  161. Abstract 95422026-09-03 · 18:00 CT · S100A
    Imfinzi plus chemotherapy in previously untreated NSCLC: updated analysis from PACIFIC-709
    G. Curigliano, M. Reck, C. Robert, et al. · Cleveland Clinic
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  162. Abstract 93782026-09-03 · 21:15 CT · S406
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-449 study)
    M. Krop, T. Mok, C. Saura, et al. · Memorial Sloan Kettering Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  163. Abstract 91172026-09-02 · 18:30 CT · E450
    PACIFIC-537: Imfinzi (durvalumab) adjuvant in NSCLC
    G. Curigliano, H. Rugo, M. Reck, et al. · Peter MacCallum Cancer Centre
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  164. Abstract 90222026-09-01 · 13:00 CT · S406
    Long-term follow-up of Keytruda neoadjuvant for SCLC: KEYNOTE-79
    R. Herbst, S. Antonia · Peter MacCallum Cancer Centre
    Poster SessionLung Cancer—Small Cell📄🖼️
  165. Abstract 97562026-09-04 · 18:45 CT · E450
    Biomarker subgroup analysis of Enhertu in NSCLC (the DESTINY-Breast-141 study)
    C. Saura, S. Modi · Royal Marsden Hospital
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  166. Abstract 94452026-09-02 · 21:30 CT · S406
    Tecentriq plus chemotherapy in previously untreated NSCLC: updated analysis from IMpower-460
    C. Robert, J. Cortes, T. Mok · Massachusetts General Hospital
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  167. Abstract 97762026-09-02 · 20:15 CT · E450
    Tecentriq plus chemotherapy in previously untreated NSCLC: updated analysis from IMpower-783
    R. Herbst, E. Winer, H. Rugo, et al. · Institut Gustave Roussy
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  168. Abstract 93992026-09-02 · 13:00 CT · E450
    Long-term follow-up of Tagrisso maintenance for NSCLC: FLAURA-996
    G. Curigliano, E. Winer · Cleveland Clinic
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  169. Abstract 96802026-09-01 · 15:15 CT · Arie Crown Theater
    Biomarker subgroup analysis of Tecentriq in NSCLC (the IMpower-772 study)
    A. Spira, G. Curigliano, T. Mok, et al. · Mayo Clinic
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  170. Abstract 96572026-09-01 · 14:45 CT · Arie Crown Theater
    Imfinzi plus chemotherapy in previously untreated NSCLC: updated analysis from PACIFIC-767
    S. Antonia, T. Mok, R. Herbst · Mayo Clinic
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  171. Abstract 92812026-09-02 · 19:15 CT · E450
    Long-term follow-up of Imfinzi 2L for SCLC: PACIFIC-264
    S. Tolaney, S. Antonia, N. Rizvi, et al. · National Cancer Center Japan
    Poster SessionLung Cancer—Small Cell📄🖼️
  172. Abstract 93682026-09-02 · 18:30 CT · S406
    Biomarker subgroup analysis of Opdivo in NSCLC (the CheckMate-359 study)
    M. Reck, H. Rugo, P. Schmid · Chinese University of Hong Kong
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  173. Abstract 98962026-09-04 · 18:15 CT · S100A
    Long-term follow-up of Tagrisso 3L+ for NSCLC: FLAURA-309
    R. Herbst, C. Robert, T. Mok, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  174. Abstract 90032026-09-04 · 19:30 CT · E450
    FLAURA-221: Tagrisso (osimertinib) maintenance in NSCLC
    J. Cortes, P. Schmid · Mayo Clinic
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  175. Abstract 98162026-09-03 · 15:45 CT · Hall B1
    Long-term follow-up of Tagrisso adjuvant for NSCLC: FLAURA-587
    R. Herbst, M.C. Garassino, M. Reck, et al. · Memorial Sloan Kettering Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  176. Abstract 96772026-09-03 · 15:00 CT · Arie Crown Theater
    Long-term follow-up of Opdivo neoadjuvant for NSCLC: CheckMate-598
    C. Robert, P. Schmid, H. Rugo, et al. · Mayo Clinic
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  177. Abstract 92022026-09-05 · 15:45 CT · Hall B1
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-551
    E. Winer, J. Brahmer, F. Andre, et al. · Dana-Farber Cancer Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  178. Abstract 92742026-09-05 · 16:15 CT · S100A
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-282
    L. Paz-Ares, H. Borghaei, M. Krop, et al. · National Cancer Center Japan
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  179. Abstract 95702026-09-01 · 14:45 CT · Hall B1
    Enhertu plus chemotherapy in previously untreated NSCLC: updated analysis from DESTINY-Breast-876
    J. Cortes, H. Rugo, A. Spira, et al. · Mayo Clinic
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  180. Abstract 91972026-09-03 · 15:15 CT · S406
    Imfinzi plus chemotherapy in previously untreated NSCLC: updated analysis from PACIFIC-201
    C. Robert, E. Winer, S. Peters, et al. · Royal Marsden Hospital
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  181. Abstract 97592026-09-05 · 15:45 CT · E450
    FLAURA-964: Tagrisso (osimertinib) 3L+ in NSCLC
    R. Herbst, E. Winer, M. Krop, et al. · Massachusetts General Hospital
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  182. Abstract 97122026-09-04 · 13:00 CT · Arie Crown Theater
    Biomarker subgroup analysis of Opdivo in NSCLC (the CheckMate-622 study)
    A. Spira, P. Schmid · Memorial Sloan Kettering Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  183. Abstract 97142026-09-02 · 21:45 CT · E450
    Biomarker subgroup analysis of Enhertu in NSCLC (the DESTINY-Breast-888 study)
    A. Spira, J. Brahmer, L. Paz-Ares, et al. · MD Anderson Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  184. Abstract 90682026-09-02 · 18:00 CT · S100A
    Long-term follow-up of Tagrisso maintenance for NSCLC: FLAURA-33
    T. Mok, M.C. Garassino, M. Reck, et al. · Cleveland Clinic
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  185. Abstract 91262026-09-04 · 16:15 CT · S100A
    Long-term follow-up of Tagrisso 3L+ for NSCLC: FLAURA-720
    L. Paz-Ares, G. Curigliano · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  186. Abstract 90112026-09-04 · 19:30 CT · E450
    DESTINY-Breast-212: Enhertu (trastuzumab deruxtecan) 1L in NSCLC
    M.C. Garassino, C. Robert, J. Brahmer, et al. · Institut Gustave Roussy
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  187. Abstract 95942026-09-01 · 16:45 CT · Hall B1
    Biomarker subgroup analysis of Imfinzi in SCLC (the PACIFIC-193 study)
    L. Paz-Ares, T. Mok, N. Rizvi, et al. · Peter MacCallum Cancer Centre
    Poster SessionLung Cancer—Small Cell📄🖼️
  188. Abstract 99242026-09-02 · 13:15 CT · S100A
    Biomarker subgroup analysis of Imfinzi in SCLC (the PACIFIC-202 study)
    G. Curigliano, H. Borghaei, S. Peters, et al. · Peter MacCallum Cancer Centre
    Poster SessionLung Cancer—Small Cell📄🖼️
  189. Abstract 92052026-09-05 · 18:45 CT · S406
    Imfinzi plus chemotherapy in previously untreated NSCLC: updated analysis from PACIFIC-52
    J. Cortes, S. Peters, J. Brahmer, et al. · Mayo Clinic
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  190. Abstract 91272026-09-03 · 21:00 CT · S406
    FLAURA-312: Tagrisso (osimertinib) 1L in NSCLC
    S. Peters, M. Krop, N. Rizvi · Princess Margaret Cancer Centre
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  191. Abstract 93372026-09-05 · 19:00 CT · S406
    Biomarker subgroup analysis of Enhertu in NSCLC (the DESTINY-Breast-966 study)
    M. Reck, L. Paz-Ares, S. Modi · Karolinska Institute
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  192. Abstract 93512026-09-02 · 15:30 CT · S406
    Tecentriq plus chemotherapy in previously untreated NSCLC: updated analysis from IMpower-590
    S. Peters, A. Spira · Memorial Sloan Kettering Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  193. Abstract 91182026-09-03 · 14:15 CT · E450
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-433 study)
    J. Brahmer, F. Andre · Princess Margaret Cancer Centre
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  194. Abstract 99732026-09-04 · 21:15 CT · S100A
    CheckMate-912: Opdivo (nivolumab) adjuvant in NSCLC
    T. Mok, P. Schmid, J. Cortes, et al. · National Cancer Center Japan
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  195. Abstract 95422026-09-01 · 21:15 CT · Arie Crown Theater
    Biomarker subgroup analysis of Tecentriq in NSCLC (the IMpower-951 study)
    M. Reck, M. Krop, C. Saura, et al. · University of Chicago
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  196. Abstract 97952026-09-04 · 16:45 CT · Hall B1
    FLAURA-955: Tagrisso (osimertinib) 1L in NSCLC
    N. Rizvi, S. Modi, T. Mok · Institut Gustave Roussy
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  197. Abstract 94402026-09-01 · 20:45 CT · Arie Crown Theater
    FLAURA-581: Tagrisso (osimertinib) neoadjuvant in NSCLC
    S. Antonia, M. Krop, L. Paz-Ares · Johns Hopkins Kimmel Cancer Center
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  198. Abstract 98542026-09-01 · 15:15 CT · E450
    PACIFIC-434: Imfinzi (durvalumab) 1L in NSCLC
    J. Cortes, M. Krop, L. Paz-Ares · Peter MacCallum Cancer Centre
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  199. Abstract 92762026-09-04 · 19:30 CT · E450
    Biomarker subgroup analysis of Tecentriq in NSCLC (the IMpower-97 study)
    M.C. Garassino, M. Krop · University of Chicago
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  200. Abstract 91552026-09-03 · 20:00 CT · E450
    Biomarker subgroup analysis of Imfinzi in NSCLC (the PACIFIC-496 study)
    H. Rugo, L. Paz-Ares, J. Brahmer, et al. · Mayo Clinic
    Poster SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
© 2026 American Society of Clinical Oncology · Citations follow JCO supplement format:J Clin Oncol 44, 2026 (suppl 17; abstr XXXX). Demo mock.